Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight

作者：Se‐Jin Lee, Adam Lehar, Jessica Ulrika Meir, Christina Koch, Andrew John Morgan, L. E. Warren, Renata Rydzik, Daniel W. Youngstrom, Harshpreet Chandok, Joshy George, Joseph Gogain, Michael Michaud, Thomas A. Stoklasek, Yewei Liu, Emily L. Germain‐Lee · 发表于：Proceedings of the National Academy of Sciences · 年份：2020 · DOI：10.1073/pnas.2014716117 · 被引用次数：118 · 研究领域：Muscle Physiology and Disorders、Spaceflight effects on biology、Muscle metabolism and nutrition

mice, were largely maintained during spaceflight. Systemic inhibition of MSTN/activin A signaling using a soluble form of the activin type IIB receptor (ACVR2B), which can bind each of these ligands, led to dramatic increases in both muscle and bone mass, with effects being comparable in ground and flight mice. Exposure to microgravity and treatment with the soluble receptor each led to alterations in numerous signaling pathways, which were reflected in changes in levels of key signaling components in the blood as well as their RNA expression levels in muscle and bone. These findings have implications for therapeutic strategies to combat the concomitant muscle and bone loss occurring in people afflicted with disuse atrophy on Earth as well as in astronauts in space, especially during prolonged missions.